BREAKTHROUGH: AI-led Drug Discovery Programme Identifies Promising Flu Targets
Poolbeg Pharma has made a major breakthrough in its AI-led drug discovery programme, with the endorsement of its influenza drug targets by its Scientific Advisory Board (SAB). The SAB, consisting of experts in the field, has validated the prioritised targets obtained through Poolbeg’s collaboration with CytoReason. This collaboration has led to the identification of a large number of novel drug targets, and after preliminary evaluations, a prioritised list was formed. Lab-based validation is expected to be completed by 2024.
Unleashing the power of artificial intelligence, Poolbeg’s collaboration with CytoReason has resulted in the discovery of multiple new influenza drug targets in just 15 months. This is a testament to the speed and efficiency of AI-enabled discovery. The endorsement by the SAB is a crucial step in bringing these new candidates to potential partners and generating returns on the company’s research and development efforts.
The use of AI in drug discovery is gaining global interest, with major pharmaceutical companies investing heavily in this space. AI offers a faster, more cost-effective, and higher success rate in target identification. This is particularly relevant to influenza, a disease that affects millions worldwide and lacks effective treatments. Poolbeg and CytoReason’s innovative approach of targeting genes involved in the disease’s progression is attracting attention from industry players and potential partners.
Lab validation of the identified targets is set to be completed in 2024, presenting a potential turning point for Poolbeg Pharma. The company has already made significant progress across its portfolio, including strong clinical trial data for its flagship candidate POLB 001, which has potential applications in severe influenza and other acute inflammatory conditions. Poolbeg is also in discussions with potential oncology partners for POLB 001, with an agreement expected to be signed soon.
As Poolbeg Pharma continues to revolutionize the field of drug discovery with the help of AI technology, the question remains: will this groundbreaking approach pave the way for transformative treatments and a brighter future in healthcare? Share your thoughts in the comments below!
IntelliPrompt curated this article: Read the full story at the original source by clicking here